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TCT-391
Red Blood Cell Transfusion and Long-term Major Adverse Events in Patients
Undergoing Percutaneous Coronary Interventions, Results from A Large
Prospective Multicenter Registry – the STENT Group
Hiroki Ito1, Matthew Cantrell1, Marcy Nussbaum2, James Hermiller1, Zachary
Hodes1, Charles Simonton2
1St. Vincent Heart Center of Indiana, Indianapolis, IN; 2Carolinas Medical Center,
Charlotte, NC
Background: Independent association between red blood cell transfusion (RBCT) and
all cause death has been reported in patients undergoing percutaneous coronary
interventions (PCI).
Methods: We utilized a subset of the STENT study, who underwent PCI during May
2003 - June 2006. All cause death, myocardial infarction (MI), and target vessel
revascularization (TVR) were used as the study outcomes. A propensity score model
was created to predict receiving RBCT. A one to five ratio of propensity score matched
patients with and without RBCT was used to produce adjusted Cox proportional hazard
ratios (HR).
Results: Of the total population (N=19,893), 570 patients (2.9%) received RBCT and
156 (0.78%) complicated with TIMI major bleeding. The study outcomes at 9 months
included all cause death 704 patients (3.5%), MI 611 (3.1%), and TVR 1093 (5.6%).
The propensity score model consisted of 24 baseline variables including hemoglobin
levels and had excellent fit for predicting RBCT (c-statistic 0.85). Adjusted HR of 9-
month all-cause death, MI and TVR comparing patients with and without RBCT were
2.3 (95% confidence interval: 1.6-3.1), 2.2 (1.6-3.2) and 2.1 (1.5-3.0), respectively.
RBCT remained as a significant predictor when adjusted with propensity score + TIMI
major bleeding event for the all outcomes: adjusted HR 2.3 (1.7-3.3), 2.2 (1.5-3.4) and
1.9 (1.3-2.8), respectively.
Conclusion: We demonstrated the independent association between RBCT and 9-
month major adverse events in patients undergoing PCI. A randomized trial of RBCT
strategies may be warranted to guide clinical practice.
TCT-392
The Frequency and Etiology of Readmission in the 30 days After Percutaneous
Coronary Intervention
Gregory W Yost, Stefanie L Puher, Thomas D Scott, Kimberly A Skelding, Donald
Nardone, John McB Hodgson, Peter B Berger, James C Blankenship
Geisinger Medical Center, Danville, PA
Background: Readmissions after percutaneous coronary intervention (PCI) are costly
and associated with increased mortality. Identifying the frequency and causes may lead
to strategies to prevent readmission.
Methods: Patients undergoing PCI (elective, urgent, and emergent) at our center
between 1/1/2007 and 4/12/2010 were prospectively entered into the American College
of Cardiology National Cardiovascular Data Registry (n=4,523). Patients readmitted
within 30 days of the index procedure were identified using an administrative database
(n=222). Phone calls to all PCI patients at 1 year identified 48 additional patients
readmitted to a non-Geisinger hospital. Individual charts were reviewed independently
by 2 investigators, and disagreements regarding cause for readmission were resolved
by a 3rd investigator. Reasons for readmission were categorized as: PCI complication,
cardiac cause related to index admission, non-cardiac cause related to index admission,
and unrelated to index admission. Variables associated with readmission with p<0.1
were considered for inclusion in a multivariable logistic regression model predicting
30-day readmission.
Results: Of 4,523 cases included for analysis, 222 (4.9%) were readmitted within 30
days. Thirty (14%) were due to a PCI complication, 87 (39%) were non-PCI related
but cardiac related to index admission, 13 (6%) were non-cardiac but related to index
admission, and 92 (41%) were not related to the index admission. Female sex, advanced
age, peripheral arterial disease, prior valvular surgery, and PCI complications during
index procedure were associated with higher likelihood of 30-day readmission.
Conclusion: After PCI, readmission within 30 days due to PCI complications is rare
(0.6% of all PCI). Most predictors of readmission are not modifiable (sex, age, prior
valve surgery, or urgent status of procedure). PCI complications are modifiable risk
factors, but eliminating all of these would have a small affect on the overall readmission
rate. 30-day readmission should not be used as a lone metric of quality of PCI
performance.
TCT-393
Incidence, predictors and long-term clinical outcomes of coronary perforation
in the modern era
Samer Mansour, Alexis Matteau, Francois Gobeil, Andre Kokis, Louis-Mathieu
Stevens, Nicolas Noiseux
Centre hospitalier de l’Universite de Montreal, Montreal, Canada
Background: Coronary perforation is a rare but life-threatening complication of
percutaneous coronary intervention (PCI). We aim to evaluate the incidence, predictors,
management, and clinical outcomes of patients with procedure-related coronary
perforation in the modern era.
Methods: We performed a database analysis in a Canadian high-volume tertiary center.
Clinical and procedural records and angiographic studies were reviewed. In-hospital
and long-term clinical follow-up were obtained.
Results: Between June 2008 and March 2011, 6647 patients underwent PCI.Coronary
perforation was noted in 20 patient(0.3%).The perforation population was notable for
its advanced age (73 +/- 9 years), high incidence of female sex (55%) and presentation
in acute coronary syndrome (65%) (All, P < .001 compared with patients without
perforation). Most lesions were complex (60% type C) and located in the right coronary
artery (40%). The perforation occurred following stenting in 30% and mostly post-
stenting dilatation with a non-compliant balloon in 65% of patients. No
rotablation-related perforation was noted. Type III perforation was noted in the majority
of cases (60%). Following perforation, immediate successful treatment was obtained
with prolonged balloon inflation in one case and covered stent implantation in 19 cases.
More than one stent graft was needed in 25% and urgent coronary artery bypass graft
surgery (CABG) and surgical repair was required in 2 cases because of covered stent
failure. During the procedure 55% (n=11) had hemodynamic instability/required
cardiopulmonary resuscitation and one patient died. The in-hospital myocardial
infarction (MI) rate was 60% (n=12), stroke rate was 5% (n=1) and target lesion
revascularisation (TLR) rate was 5% (n=1). The mean length of hospital stay was (7
+/- 6 days). At clinical follow-up (n=19, median: 482, range: 29-1030 days) no MI or
stroke was noted, however one patient (5%) died from an unknown cause one month
after the procedure and 2 patients (10%) required TLR (one CABG and one re-PCI).
Conclusion: Despite more aggressive approach with PCI to treat coronary artery
disease in the recent years, coronary perforation remains a rare complication associated
with complex lesions. However, it still implies significant morbidity and mortality.
TCT-394
Early and Long Term Results After Five–Hours Discharge Percutaneous
Coronary Interventions
R. Stefan Kiesz1, Magda D Konkolewska1, Radoslaw J Szymanski2, Barbara K
Wiernek2, Szymon L Wiernek2, Pawel E Buszman2
1San Antonio Endovascular & Heart Institute, San Antonio, TX; 2American Heart of
Poland, Katowice, Poland
Background: Since the first coronary angioplasty performed by Dr Andreas Gruntzig
in 1977, we have been witnessing the tremendous improvement in interventional
cardiology. New devices, stents, medical therapy and techniques contribute to the
improvement of safety, despite the increasing complexity of performed interventions.
We believe that, by combining direct thrombin inhibitor (Bivalirudin) with Vascular
Closure Devices, these developments allow us to safely discharge selected group of
patients 5 hours after Percutaneous Coronary Interventions (PCI). The aim of this study
was to evaluate early and late results of patients discharged on the same day after PCI.
Methods: Between December 2007 and April 2011, a total of 233 PCIs were
performed in 133 elective patients (66.9% Male). The mean age of patients was 57
(±10), 31.7% of the population was represented by Hispanics, 39.5% suffered from
diabetes and mean BMI was 31.1 (±7.6). All procedures were done with exclusive
usage of Bivalirudin and Mynx™ Vascular Closure Device. Patients were discharged
on average 4(+/- 2.5) hours after the procedure and treated with statins, dual antiplatelet
therapy and aggressive diabetes management (goal HbA1C<7). In the 30 day
observation, the primary end point (MACCE) was: Death, Myocardial Infarction,
Stroke and Target Vessel Revascularization (TVR); the secondary end point included
bleeding and vascular complications (retroperitoneal bleeding, urgent hospitalization,
pseudoaneurysm, hematoma, ecchymosis).
Results: During the mean follow-up time of 13.3 months (±10.8), the primary end
point was reached in 18 cases (7.7%), including 2 deaths (0.8%) and 16 TVRs (6.9%).
MACCE occurred on average 15.5 months (±8.2 months) after the procedure.
Secondary end point was noted in 37 (15.9%) cases including 34 ecchymoses, 1
hematoma <5cm, 1 pseudoaneurysm and 1 overnight hospital transfer.
Conclusion: This study suggests that five hours discharge after uncomplicated, elective
PCI via the femoral artery, performed by experienced operator in selected group of
patients ensures low complication rates and is both: feasible and safe.
TCT-395
Study Modifications and Primary Endpoint Reinterpretations Prior to FDA
Approval of High-Risk Cardiovascular Devices
Sanket S. Dhruva1, Lucy H Liu2, Lisa A Bero1, Rita F Redberg1
1UCSF, San Francisco, CA; 2Johns Hopkins University School of Medicine,
Baltimore, MD
Background: Study modifications and primary endpoint reinterpretations introduce
bias and reduce the certainty of research findings. Premarket Approval (PMA) is the
most rigorous Food & Drug Administration (FDA) review process, for novel and high-
risk devices, including coronary and non-coronary stents. It is unknown to what extent
study modifications and primary endpoint reinterpretations are used in PMA
applications.
Methods: We examined the Summary of Safety and Effectiveness Data for all PMA
cardiovascular devices approved from 2000 through 2010 and recorded all study
modifications and primary endpoint reinterpretations and compared stents to all
cardiovascular devices.
Results: Of the 29 coronary and non-coronary stent PMAs approved between 2000-
2010 with a study with at least one primary endpoint, 2 (7%) had some form of study
modification or primary endpoint reinterpretation. In contrast, of the 67 total
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cardiovascular non-stent PMAs approved during that time with a study with at least
one primary endpoint, 16 (24%) had a study modification or primary endpoint
reinterpretation. In one stent PMA, a study did not meet at least one pre-specified
primary endpoint, but the device was approved on the basis of a post-hoc data review.
In another stent PMA, pre-specified statistical analyses were changed after study
initiation.
Conclusion: The most rigorous FDA review process for devices includes numerous
forms of study modifications and primary endpoint reinterpretations, but these occur
less frequently for coronary and non-coronary stent studies. As these types of analyses
reduce confidence in conclusions, more consistent requirements for pre-specified
clinical trial outcomes will help improve the quality and consistency of the approval
process.
TCT-396
Percutaneous Coronary Intervention in Patients with Severe Left Ventricular
Dysfunction: A Meta-analysis of 19 Studies
Vijay Kunadian1, Andrew Pugh2, Weiliang Qiu3
1Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University,
Newcastle upon Tyne, United Kingdom; 2Faculty of Medical Sciences, Newcastle
University Medical School, Newcastle upon Tyne, United Kingdom; 3Channing
Laboratory, Department of Medicine, Brigham and Women’s Hospital/Harvard
Medical School, Boston, MA
Background: Coronary artery disease (CAD) is the most common cause for left
ventricular dysfunction (LVD). Coronary artery bypass surgery (CABG) results in
equivalent benefit in reducing mortality compared with medical therapy in patients
with CAD and severe LVD. However, the benefit of percutaneous coronary
intervention (PCI) in patients with severe LVD is not clear. A meta-analysis of studies
utilising PCI in patients with severe LVD (EF≤40%) was performed to determine in-
hospital (IH) and long-term (LT) [≥1year] mortality.
Methods: A systematic computerised literature search was performed. Studies of
patients undergoing PCI for CAD in the presence of severe LVD were included. Studies
that did not report LT mortality and same centre studies were excluded.
Results: In total, 4766 patients (19 studies) were included. The mean (pooled estimate)
age was 64.7 years with a mean (estimate) EF of 29.9% and 79.7% were men. The IH
mortality rate using random effects model (13 studies, total PCI n=2202, 39 deaths)
was 1.8% (95% CI 1.0-2.9%). The LT mortality rate (23.86 months) using random
effects model (19 studies, total follow-up n=2937, 401 deaths) was 15.6% (95% CI
11.0-20.7%). Five studies compared PCI versus CABG (n=455 vs. n=502) and provide
LT mortality data (PCI n=102 vs. CABG n=115 deaths). The relative risk using random
effects model (PCI vs. CABG) was 0.98 (95% CI 0.78-1.22, p value 0.83).
Long-term Mortality Following PCI in Severe LV Dysfunction: A Meta-analysis
Conclusion: This meta-analysis demonstrates that based on available clinical studies,
PCI among patients with severe LVD is feasible with acceptable in-hospital and long-
term mortality and yields comparable outcomes with CABG.
TCT-397
Statin Therapy Reduces Late Target Lesion Revascularization After Sirolimus-
Eluting Stent Implantation
Masahiro Natsuaki1, Takeshi Morimoto2, Yutaka Furukawa3, Satoshi Shizuta1, Toru
Kita3, Takeshi Kimura1
1Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto
University, Kyoto, Japan; 2Center for Medical Education and Clinical Epidemiology
Unit, Graduate School of Medicine, Kyoto University, Kyoto, Japan; 3Division of
Cardiology, Kobe City Medical Center General Hospital, Kobe, Japan
Background: Late catch-up phenomenon in target lesion revascularization (TLR) is
one of the problems after sirolimus-eluting stent (SES) implantation. However, the
way to reduce late TLR after SES implantation has not been established.
Methods: Among 13087 patients undergoing first percutaneous coronary intervention
in the CREDO-Kyoto registry Cohort-2 from January 2005 to December 2007, 10221
patients were implanted only SES (SES stratum: 5029) or only bare-metal stent (BMS)
(BMS stratum: 5192). To evaluate the impact of statin therapy on late TLR (1-year to
4-year), SES implanted patients were divided into 2 groups according to the statin
therapy at discharge (statin group: 2735, non-statin group: 2294). BMS implanted
patients were also divided into 2576 statin and 2616 non-statin group.
Results: Incidence of late TLR was significantly higher in SES implanted patients
compared to BMS implanted patients (7.7% vs. 3.0%, P<0.0001). In SES stratum,
incidence of late TLR was significantly lower in the statin group than in the non-statin
group (6.1% vs. 9.6%, P=0.002), although no significant difference was found in BMS
stratum (2.6% vs. 3.3%, P=0.38). After adjusting confounders, the risk for late TLR
was significantly lower in the statin group in SES stratum (hazard ratio (HR) 0.66 [95%
confidence interval (CI) 0.50-0.88], P=0.004), although the risk was comparable in
BMS stratum (HR 0.83 [95% CI 0.52-1.31], P=0.42).
Conclusion: Incidence of late TLR was significantly higher in SES than in BMS
implanted patients. Statin therapy significantly reduced late TRL after SES
implantation, although significant risk reduction was not found after BMS
implantation.
TCT-398
Married Patients Suffer Less Death and Myocardial Infarction After
Percutaneous Coronary Intervention
Michael A Gaglia, Rebecca Torguson, Zhenyi Xue, Itsik Ben-Dor, Gabriel Maluenda,
Gabriel Sardi, Israel Barbash, William O Suddath, Kenneth M Kent, Lowell F Satler,
Augusto D Pichard, Ron Waksman
Cardiology Dept., Washington Hospital Center, Washington, DC
Background: Socioeconomic factors such as insurance and household income impact
cardiovascular risk and outcomes, but the influence of marital status upon outcomes
following PCI is poorly understood.
Methods: We compared 2971 currently married patients to 2213 unmarried patients,
defined as single, widowed, divorced or separated, at one year following PCI. Patients
were followed for 1 year in regards to the combined endpoint of all-cause death and
MI; the latter was defined as CK-MB elevation ≥2 times upper limit of normal and/or
new Q waves or ST elevation ≥1 mm. Multivariable Cox proportional hazards
regression was performed to adjust for confounders.
Results: Married patients, compared to unmarried patients, were more likely to be
male (76.3% v. 53.6%) or Caucasian (77.0% v. 59.4%) and were less likely to present
with acute coronary syndrome (10.1% v. 16.5%) or have congestive heart failure
(11.1% v. 15.8%) or chronic renal insufficiency (8.8% vs. 14.2%; p<0.001 for all
comparisons). Unadjusted 1-year death (3.2% v. 7.4%, p<0.001) and death plus MI
(4.3% v. 9.6%, p<0.001) were lower among married patients compared to married
patients, as was definite and probable stent thrombosis (0.4% v. 1.2%, p=0.002).
Following multivariable adjustment, being married remained associated with lower
rates of death and MI at 1 year (HR 1.63, 95% CI 1.29-2.07, p<0.001; Table).
Conclusion: The presence of social support, possibly by ensuring better medication
compliance, lifestyle modification and follow-up, improves outcomes following PCI.
TCT-399
Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO®): Results
From the First-In-Man Prepare PICSO® Pilot Study
Tim Pieter van de Hoef, Froukje Nolte, Ronak Delewi, M. Cristina Rolandi, José P
Henriques, Jos A Spaan, Maria Siebes, Joanna J Wykrzykowska, Jan J Piek
Academic Medical Center Amsterdam, Amsterdam, Netherlands
Background: Pressure-controlled intermittent coronary sinus occlusion (PICSO®)
may serve as an adjuvant therapy in acute myocardial infarction by augmenting
redistribution of blood to the border zone of the ischemic myocardium. This first-in-
man study evaluated safety and feasibility of PICSO®, and its effect on coronary
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